SynthesisCurrent psychiatry reports2015
Management of adverse effects of mood stabilizers.
Synthesis in Current psychiatry reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- Weight changes associated with antiepileptic mood stabilizers in the treatment of bipolar disorder.European journal of clinical pharmacology · 2018Pooled it
- Breaking Barriers Transforming Primary Care to Serve the Physical Health Needs of Individuals With SMI in the NHS.International journal of mental health nursing · 2025Review
- Article
- Lithium Treatment Induces Cardiac Dysfunction in Mice.International journal of molecular sciences · 2023Article
- Mycotherapy: Potential of Fungal Bioactives for the Treatment of Mental Health Disorders and Morbidities of Chronic Pain.Journal of fungi (Basel, Switzerland) · 2022Review
- Bipolar depression: a review of treatment options.General psychiatry · 2022Review
- Psychotropics and COVID-19: An analysis of safety and prophylaxis.L'Encephale · 2021Article
- Inositols: From Established Knowledge to Novel Approaches.International journal of molecular sciences · 2021Review
- Long-Term Real-World Effectiveness of Pharmacotherapies for Schizoaffective Disorder.Schizophrenia bulletin · 2021Article
- Inositols Depletion and Resistance: Principal Mechanisms and Therapeutic Strategies.International journal of molecular sciences · 2021Review
- Hamlet's augury: how to manage discontinuation of mood stabilizers in bipolar disorder.Therapeutic advances in psychopharmacology · 2021Review
- Factors Associated with Doses of Mood Stabilizers in Real-world Outpatients with Bipolar Disorder.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2020Article
- Safety of psychotropic medications in people with COVID-19: evidence review and practical recommendations.BMC medicine · 2020Review
- Association between sleep quality and domains of quality of life amongst patients with first episode psychosis.Health and quality of life outcomes · 2020Article
- How Can Drug Metabolism and Transporter Genetics Inform Psychotropic Prescribing?Frontiers in genetics · 2020Review
- Article
- The impact of severe mental disorders and psychotropic medications on sexual health and its implications for clinical management.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2018Article
- The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm.The international journal of neuropsychopharmacology · 2017Review
- Adverse Renal, Endocrine, Hepatic, and Metabolic Events during Maintenance Mood Stabilizer Treatment for Bipolar Disorder: A Population-Based Cohort Study.PLoS medicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mood stabilizers such as lithium and anticonvulsants are still standard-of-care for the acute and long-term treatment of bipolar disorder (BD). This systematic review aimed to assess the prevalence of their adverse effects (AEs) and to provide recommendations on their clinical management. We performed a systematic research for studies reporting the prevalence of AEs with lithium, valproate, lamotrigine, and carbamazepine/oxcarbazepine. Management recommendations were then developed. Mood stabilizers have different tolerability profiles and are eventually associated to cognitive, dermatological, endocrine, gastrointestinal, immunological, metabolic, nephrogenic, neurologic, sexual, and teratogenic AEs. Most of those can be transient or dose-related and can be managed by optimizing drug doses to the lowest effective dose. Some rare AEs can be serious and potentially lethal, and require abrupt discontinuation of medication. Integrated medical attention is warranted for complex somatic AEs. Functional remediation and psychoeducation may help to promote awareness on BD and better medication management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.